secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2026-03-13T23:59:59+00:00
Accession:  0001828185-26-000011
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Bio reports FY2025 net loss $66.5M; merger with Clywedog on track for Q2 2026
--------------------------------------------------------------------------------

- Proposed all-stock merger with Clywedog expected to close Q2 2026; combined entity to trade as CLYD.
- Cash, cash equivalents & restricted cash $71.9M at Dec 31, 2025, down from $112.4M YoY.
- Net loss of $66.5M ($1.64 per share) in 2025 vs $61.1M ($1.55) in 2024.
- R&D expenses decreased to $25.6M from $42.2M due to deprioritization of legacy assets.
- VTP-1000 multiple ascending dose data in celiac expected H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000182818526000011/0001828185-26-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000182818526000011/brns-20260313.htm
  HTML page:      https://secwatch.observer/filing/0001828185-26-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer